Section Arrow
EXEL.NASDAQ
- Exelixis
Quotes are at least 15-min delayed:2026/03/02 12:20 EST
Regular Hours
Last
 40.74
-3.32 (-7.54%)
Day High 
43.25 
Prev. Close
44.06 
1-M High
45.87 
Volume 
4.08M 
Bid
40.72
Ask
40.77
Day Low
39.71 
Open
42 
1-M Low
40.54 
Market Cap 
11.44B 
Currency 美元 
P/E 15.37 
%Yield -- 
10-SMA 44.25 
20-SMA 43.54 
50-SMA 43.93 
52-W High 49.62 
52-W Low 32.38 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.78/4.08
Enterprise Value
11.62B
Balance Sheet
Book Value Per Share
8.32
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
2.32B
Operating Revenue Per Share
6.83
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IBRXImmunityBio10.56+0.76+7.76%-- 
OCULOcular Therapeutix10.775+1.83+20.46%-- 
QNCXQuince Therapeutics0.1061-0.014-11.66%-- 
RAPTRAPT Therapeutics Inc57.995+0.015+0.03%-- 
QUREuniQure NV10.17-5.41-34.72%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.